SecBot SecBot
SECBOTREPLAY Home › Report › LYEL

LYEL · Lyell Immunopharma presented updated Phase 1/2 safety and translational…

Lyell Immunopharma, Inc · PRESS-RELEASE filed Jun 12, 2026 at 12:45 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Jun 12, 2026 at 12:45 ET

Lyell Immunopharma presented updated Phase 1/2 safety and translational data for its CAR T-cell therapy ronde-cel at EHA 2026, including a 97% manufacturing success rate and no Grade ≥3 CRS in 108 patients with R/R LBCL, supporting potential for outpatient administration and durably differentiated responses. However, this is an interim data readout, not a pivotal regulatory event; the key catalyst is the PiNACLE trial data update expected H2 2026, with pivotal data and BLA submission not expected until mid-2027 and H2 2027, respectively.

  • 108 patients with R/R LBCL treated with ronde-cel; 97% manufacturing success rate
  • No Grade ≥3 CRS across 108 patients; Grade ≥3 ICANS in 8% (prophylaxis) vs 16% (no prophylaxis)
  • Translational data: Cytotoxic T cells with Memory Potential (Tcmp) more abundant in durable responders (>12 months) vs progressive disease
  • Durable complete responses >12 months observed even in patients with low CD19/CD20 antigen expression

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access